Markets
Agios Mitapivat Sickle Cell Trial Results: What the Data Means for AGIO Stock
Agios Pharmaceuticals has unveiled detailed clinical data for mitapivat in sickle cell disease, a pivotal moment that could reshape the company's commercial pipeline and send AGIO shares on a decisive move. Here is the full breakdown of what the trial results mean for traders and long-term investors.